TSX:ONC 1.50 CAD +0.01 +0.67% Volume: 24,344 August 29, 2014
NASDAQ:ONCY 1.38 USD +0.00 +0% Volume: 52,964 August 29, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

August 11, 2014 Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences
August 07, 2014 Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results
July 08, 2014 Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study
Sign up to receive e-mail updates *